Total RNA was extracted from renal and splenic tissues using TRIzol according to the extraction kit manufacturer’s instructions (Invitrogen, USA). One microgram of RNA was reverse-transcribed using the GoScript reverse transcription system (Promega, USA). qPCR was performed using SYBR Master Mix (Qiagen, Germany) and analyzed on a Roche Light 480II system. Relative mRNA expression levels were calculated using the 2−ΔΔCt method and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression levels. The following primer sequences were used: GAPDH, 5′-TTGATGGCAACAATCTCCAC-3′ (forward) and 5′-CGTCCCGTAGACAAAATGGT-3′ (reverse); LYVE-1, 5′-AATTTCACAGAAGCCAACGA-3′ (forward) and 5′-ATCCATAGCTGCAAGTCTC-3′ (reverse); PROX1, 5′-CTGGGCCAATTATCACCAGT-3′ (forward) and 5′-GCCATCTTCAAAAGCTCGTC-3′ (reverse); VEGF-C, 5′-CAGCAAGACGTTGTTTGAAATTACA-3′ (forward) and 5′-GTGATTGGCAAAACTGATTGTGA-3′ (reverse); VEGF-D, 5′-AAATCGCGCACTCTGAGGA-3′ (forward) and 5′-TGGCAAGACTTTTGAGCTTCAA-3′ (reverse); FGF-2, 5′-AGCGGCTCTACTGCAAGAAC-3′ (forward) and 5′-TGGCACACACTCCCTTGATA-3′ (reverse); VEGF164, 5′-ACAGCAGATGTGAATGCAGACCAAAGAAAG-3′ (forward) and 5′-CAAGGCTCACAGTGATTTTCTGG-3′ (reverse); IL-2, 5′-CCTTCAAATTTTACTTGCCCA-3′ (forward) and 5′-TGAGTCAAATCCAGAACATGC-3′ (reverse); TNF-α, 5′-CATCTTCTCAAAATTCGAGTGACAA-3′ (forward) and 5′-TGGGAGTAGACAAGGTACAACCC-3′ (reverse); IL-1β, 5′-ACGGACCCCAAAAGATGAAG-3′ (forward) and 5′-TACTGCCTGCCTGAAGCTCT-3′ (reverse); IFN-γ, 5′-ACAATGAACGCTACACACTGCAT-3′ (forward) and 5′-TGGCAGTAACAGCCAGAAACA-3′ (reverse); IL-4, 5′-GGTCTCAACCCCCAGCTAGT-3′ (forward) and 5′-GCCGATGATCTCTCTCAAGTGAT-3′ (reverse); IL-6, 5′-GCCTTCCCTACTTCACAAGT-3′ (forward) and 5′-GAATTGCCATTGCACAACTCT-3′ (reverse); IL-10, 5′-GCTCTTACTGACTGGCATGAG-3′ (forward) and 5′-CGCAGCTCTAGGAGCATGTG-3′ (reverse); T-BET, 5′-ATGTTTGTGGATGTGGTCTTGGT-3′ (forward) and 5′-CGGTTCCCTGGCATGCT-3′ (reverse); GATA3, 5′-CTCGGCCATTCGTACATGGAA-3′ (forward) and 5′-GGATACCTCTGCACCGTAGC-3′ (reverse); RORγt, 5′-TACCTTGGCCAAAACAGAGG-3′ (forward) and 5′-ATGCCTGGTTTCCTCAAAA-3′ (reverse); FOXP3, 5′-TGCAGGGCAGCTAGGTACTTG-3′ (forward) and 5′-TCGGAGATCCCCTTTGTCTTATC-3′ (reverse); GZMB, 5′-TCGACCCTACATGGCCTTAC-3′ (forward) and 5′-TGGGGAATGCATTTTACCAT-3′ (reverse); MIF, 5′-AGTAAGCTGCTGTGTGGCCTGCT-3′ (forward) and 5′-CAGGACTCAAGCGAAGGTGGAAC-3′ (reverse); CCL2, 5′-GTCTGTGCTGACCCCAAGAAG-3′ (forward) and 5′-TGGTTCCGATCCAGGTTTTTA-3′ (reverse); CCL3, 5′-TGCAACCAAGTCTTCTCAGC-3′ (forward) and 5′-GCCGGTTTCTCTTAGTCAGG-3′ (reverse); CX3CL1, 5′-TCGGACTTTGTTGGTTCCTC-3′ (forward) and 5′-CAAAATGGCACAGACATTGG-3′ (reverse); CXCL10, 5′-CCAAGTGCTGCCGTCATTTTC-3′ (forward) and 5′-TCCCTATGGCCCTCATTCTCA-3′ (reverse); CXCL12, 5′-CATCCATCCATCCATCCA-3′ (forward) and 5′-TTCAGGGTCATGGAGACAGT-3′ (reverse); TGFβ1, 5′-CAACAATTCCTGGCGTTACCTT-3′ (forward) and 5′-TCGAAAGCCCTGTATTCCGTCT-3′ (reverse); CTGF, 5′-AGCCTCAAACTCCAAACACC-3′ (forward) and 5′-CAACAGGGATTTGACCAC-3′ (reverse); PDGFBB, 5′-CCCACAGTGGCTTTTCATTT-3′ (forward) and 5′-GTGAACGTAGGGGAAGTGGA-3′ (reverse); PDGFRB, 5′-ACCAGCGAGGTTTCACTGGTACTT-3′ (forward) and 5′-ATCATTGCCCATCACAATGCACCG-3′ (reverse); ACTA2, 5′-GTCCCAGACATCAGGGAGTAA-3′ (forward) and 5′-TCGGATACTTCAGCGTCAGGA-3′ (reverse); fibronectin, 5′-GCTCAGCAAATCGTGCAGC-3′ (forward) and 5′-CTAGGTAGGTCCGTTCCCACT-3′ (reverse); RIP3, 5′-CAGTGGGACTTCGTGTCCG-3′ (forward) and 5′-CAAGCTGTGTAGGTAGCACATC-3′ (reverse); SLC22A6, 5′-CTGATGGCTTCCCACAACAC-3′ (forward) and 5′-GTCCTTGCTTGTCCAGGGG-3′ (reverse); Ki67, 5′-CAGTACTCGGAATGCAGCAA-3′ (forward) and 5′-CAGTCTTCAGGGGCTCTGTC-3′ (reverse); STMN1, 5′-CTTGCGAGAGAAGGACAAGC-3′ (forward) and 5′-CGGTCCTACATCGGCTTCTA-3′ (reverse); CD86, 5′-CCCAGATGCACCATGGGCTTGGCAA-3′ (forward) and 5′-AAGCTCGTGCGGCCCAGGTACT-3′ (reverse); CCL19, 5′-ATGTGAATCACTCTGGCCCAGGAA-3′ (forward) and 5′-AAGCGGCTTTATTGGAAGCTCTGC-3′ (reverse). CCL21a primers for spleen and CCL21b primers for kidney were purchased from GeneCopoeia (Guangzhou, China).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.